High Blood Sugar Levels Could Contribute to Alzheimer’s

Jeannette Y. Wick, RPh, MBA, FASCP
Published Online: Friday, June 7, 2013
Follow Pharmacy_Times:
A study suggests that serum glucose levels that are elevated but not high enough to diagnose diabetes may indicate an elevated risk for Alzheimer’s disease.

Studies published over the last few years have found an association between diabetes and an increased risk of developing Alzheimer’s disease. In particular, PET scans have found that Alzheimer’s patients often have reduced cerebral metabolic rates for glucose in specific brain areas. In light of these findings, researchers looking for ways to prevent Alzheimer’s believe that examining elevated fasting serum glucose and factors that regulate glucose control in cognitively normal individuals who don’t have diabetes may help reveal the etiology of Alzheimer’s.
Now, a study in this vein has found a cause-and-effect relationship between elevated blood sugar levels in patients without diabetes and an increased risk of developing Alzheimer’s. The study was conducted by researchers at the University of Arizona and published in the April 23, 2013, issue of Neurology.
The researchers examined 124 patients between the ages of 47 and 68 who had a first-degree relative with Alzheimer’s. All participants had normal brain function and did not have diabetes. The participants’ brain activity was observed using PET scans, with specific attention devoted to activity related to factors involved in regulating glucose control.
The results indicated that participants with elevated fasting blood sugar levels had patterns of reduced brain metabolism similar to those of patients diagnosed with Alzheimer’s. The findings were present and similar in both non-carriers and carriers of the APOE e4 allele, which is a significant risk factor for Alzheimer’s. This suggests that serum glucose levels that are elevated but not high enough to diagnose diabetes may indicate a risk for Alzheimer’s unrelated to one’s APOE e4 status.
The researchers suggested that additional studies “consider metabolic dysfunction as a target for AD prevention trials, such as the use of intranasal insulin.” Researchers have traditionally employed retrospective, case controlled, prospective cohort studies to assess Alzheimer’s risk factors and to design effective preventive interventions. This can be very time-consuming, but the new study suggests that using PET scans can complement the traditional approach and produce results more rapidly.
Ms. Wick is a visiting professor at the University of Connecticut School of Pharmacy and a freelance writer from Virginia.

Related Articles
In light of misrepresented statistics and overstated fears about statin-related adverse events, here are 3 of the biggest myths your patients may have heard about these life-saving medications—and the facts
Beyond working in traditional retail, community, and health-system settings, pharmacy students have a lot of options. Two Roosevelt University pharmacy students are proof of that.
Sanofi has announced the FDA approval of its insulin glargine injection (Toujeo), a once-daily long-acting basal insulin, for the improvement of glycemic control in adults with type 1 and type 2 diabetes.
Novo Nordisk has positive results from a completed phase 2 trial on the oral formulation of its investigational, long-acting human glucagon-like peptide-1 analogue.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times